JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor effective against both EGFR tyrosine kinase inhibitor (TKI)-sensitive and -resistant models; it potently suppresses phosphorylation of EGFR, Akt, and ERK1/2 and can be used in research on EGFR-mutant lung cancer.